Short-Term Therapy with High Dose Atorvastatin in Patients with Coronary Artery Disease Can Reduce Inflammatory Process

August 2010
Acta Medica Iranica;2010, Vol. 48 Issue 4, p218
Academic Journal
No abstract available.


Related Articles

  • Effects of Ezetimibe on Endothelial Progenitor Cells and Microparticles in High-Risk Patients. Lins, Lívia; França, Carolina; Fonseca, Francisco; Barbosa, Simone; Matos, Lívia; Aguirre, Ana; Bianco, Henrique; Amaral, Jonatas; Izar, Maria // Cell Biochemistry & Biophysics;Sep2014, Vol. 70 Issue 1, p687 

    Imbalance on endothelial turnover can predict cardiovascular outcomes. We aimed at evaluating the effects of lipid-modifying therapies on circulating endothelial progenitor cells (EPCs), endothelial microparticles (EMPs), and platelet microparticles (PMPs) in high cardiovascular risk subjects...

  • Research brief: Statins and acute coronary syndrome.  // GP: General Practitioner;9/6/2004, p10 

    The article cites that patients given 40mg/day simvastatin for a month followed by 80mg/day thereafter did not have a better outcome at the acute coronary event than those given placebo for four months followed by 20mg/day simvastatin. The international trial involving more than 4,400 patients...

  • Is Jupiter Also a God of Primary Prevention? Accad, Michel; Fred, Herbert L. // Texas Heart Institute Journal;2010, Vol. 37 Issue 1, p6 

    The article focuses on the clinical research trial named Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The trial included 17,802 healthy middle-aged men and women who did not have hyperlipidemia but did have elevated level of...

  • Predicting the potential effect of JUPITER. Weintraub, Howard; Gagarin, Dimitri // Cardiology Today;Nov2008, Vol. 11 Issue 11, p1 

    The article discusses the use of the JUPITER trial in understanding inflammation in cardiovascular disease (CVD) and the effectiveness of statin in primary prevention. The JUPITER trial determines whether long-term treatment with 20 milligrams (mg)/day of rosuvastatin would reduce the rate of...

  • Adding niacin to statins is better than ezetimibe.  // Pulse;11/25/2009, Vol. 69 Issue 38, p11 

    The article presents a study that shows adding niacin to a statin presents better results than adding ezetimibe. A U.S. study has discovered that adding niacin to a statin in coronary heart disease patients results in less major cardiovascular events than with ezetimibe. The study showed that 1%...

  • Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease. Toyama, Kensuke; Sugiyama, Seigo; Oka, Hideki; Iwasaki, Yuri; Sumida, Hitoshi; Tanaka, Tomoko; Tayama, Shinji; Jinnouchi, Hideaki; Ogawa, Hisao // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Objective: Statin- and exercise-therapy are both clinically beneficial by preventing cardiovascular events in patients with coronary artery disease (CAD). However, there is no information on the vascular effects of the combination of statins and exercise on arterial wall stiffness in CAD...

  • Early, Intensive and Long-term Statin Therapy in Acute Coronary Syndrome: Focus on Anti-inflammatory Mechanisms. Jian-Jun Li; Sheng-Shou Hu // Vascular Disease Prevention;Jul2005, Vol. 2 Issue 3, p181 

    An acceptable concept is that the acute coronary syndrome (ACS) is related to erosion or rupture of vulnerable plaques leading to intracoronary thrombosis as a result of the activation of the coagulation cascade and platelet aggregation. Clinical trials and animal models suggest an inflammatory...

  • JUPITER: C-reactive Protein a Marker for CV Events? Elliott, William T. // Infectious Disease Alert;Jan2009 Pharmacology Watch, p1 

    The article presents the findings of the JUPITER trial published in November 2008. Results suggest that elevated high-sensitivity C-reactive protein (CRP) may help identify healthy patients with normal cholesterol levels who will benefit from statin therapy. The authors of the research...

  • The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia. BAYS, HAROLD E.; ROTH, ELI M.; MCKENNEY, JAMES M.; KELLY, MAUREEN T.; THAKKER, KAMLESH M.; SETZE, CAROLYN M.; OBERMEYER, KATIE; SLEEP, DARRYL J. // Diabetes Care;Sep2010, Vol. 33 Issue 9, p2113 

    OBJECTIVE -- To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. RESEARCH DESIGN AND METHODS-- Post hoc analysis of over 2,000 metabolic syndrome patients administered...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics